REFERENCES
- Brogden RN, Buckley MM-T, Ward A. Buserelin; A review of its Pharmacodynamic and Pharmacokinetic Properties, and Clinical Profile. Drugs 1990; 39: 339–437.
- Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 1991; 265: 618–621.
- Citrin DL, Resnick MI, Guinan P, et al. A comparison of Zoladex and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial. Prostate 1991; 18: 139–146.
- Crawford ED. Hormonal therapy of prostatic carcinoma. Cancer 1990; 66: 1035–1038.
- DeVoogt HJ, Klijn JGM, Studer U, Schröder F, Sylvester R,DePauw and members of the EORTC-GU Group. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-Trial 30843. J Steroid Bio-chem Mol Biol 1990; 37: 965–969.
- DeVoogt HJ, Adenauer H, Widra WG. The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. Scand J Urol Nephrol 1991; (Suppl 138): 131–136.
- Ernst DS, Hanson J, Venner PM. Uro-oncology Group of Northern Alberta. Analysis of prognostic factors in men with metastatic prostate cancer. J Urol 1991; 146: 372–376.
- Huben RP, Murphy GP, and The investigators of the national prostatic cancer project. A comparison of diethylstilbestrol or orchiectomy with Buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1988; 62: 1881–1887.
- Huhtaniemi I, Venho P, Jacobi G, Ranniko S. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer. J Androl 1991; 12: 46–53.
- Ishikawa S, Soloway MS, Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139–1142.
- Klioze SS, Miller MF, Spiro TP, and The NPCP Protocol 1700B Study Group. A randomized comparative study of Buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol (CCT) 1988; 11: S176–S182.
- Parmar H, Philips RH, Lightman SL, Edwards L. How would you like to have an orchidectomy for advanced prostatic cancer? Am J Clin Oncol (CCT) 1988; 11: S160–S168.
- Schröder F. Hormonal manipulation of prostatic cancer. Too soon for total androgen blockade? BMJ 1991; 303: 1489–1490.
- Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017–1021.
- Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 1479–1480.
- Wulff HR, Schlicting P. Medstat. A statistic program for analysis of results of clinical trials. Copenhagen 1987.